Nls pharmaceutics to participate in the bio-europe springtime partnering event

Zurich, switzerland / accesswire / march 14, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that alex zwyer, chief executive officer of nls pharmaceutics will attend the bio-europe springtime partnering event, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-to-one meetings in barcelona, spain, taking place march 18-20, 2024.
NLSP Ratings Summary
NLSP Quant Ranking